Free shipping on all orders over $ 500

Enavatuzumab

Cat. No. M24544

All AbMole products are for research use only, cannot be used for human consumption.

Enavatuzumab Structure
Synonym:

PDL192; ABT-361

Price and Availability

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.

Quality Control & Documentation
Biological Activity

Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

Chemical Information
CAS Number 1062149-33-0
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
References

[1] Shiming Ye, et al. J Immunol Res. Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells

[2] Elaine T Lam, et al. Mol Cancer Ther. Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors

[3] Ludmilla de Plater, et al. PLoS One. Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts

[4] James W Purcell, et al. Front Immunol. Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR

[5] Debra T Chao, et al. J Cancer Res Clin Oncol. Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb

Related TNF Receptor Products
Ozekibart

Ozekibart is an anti-TNFRSF10B monoclonal antibody.
TAPI-0 

TAPI-0 is a TACE (TNF-α converting enzyme; ADAM17) inhibitor with an IC50 of 100 nM.
Semapimod tetrahydrochloride

Semapimod tetrahydrochloride (CNI-1493), an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6.
BMS-566394

BMS-566394 is a potent, exceptionally selective inhibitor of TNF-α converting enzyme (TACE).
APVO603

APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.
  Catalog
Abmole Inhibitor Catalog




Keywords: Enavatuzumab, PDL192; ABT-361 supplier, TNF Receptor, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.


 
Get to Know Us
Customer Support
Resources
Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.